Top Markets
#1 GEKKO GEKKO +45.33%
#2 ADO Protocol ADO Protocol +38.72%
#3 Pons Pons +38.38%
#4 TENDIES TENDIES +36.02%
#5 Helium Helium +29.24%
#6 Prom Prom +24.36%
#7 龙虾 (Lobster) 龙虾 (Lobster) +22.31%
#8 Nillion Nillion +17.98%
#9 Main Street Yield Main Street Yield +17.48%
#10 o1.exchange o1.exchange +17.04%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
Classement en actions #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Prix de l'action
$24.98
Dernière synchronisation: 2023-04-27
Capitalisation boursière
$1.01B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Provention Bio, Inc. (PRVB)

Catégorie

Healthcare
Historique des dividendes pour Provention Bio, Inc. (PRVB)
Provention Bio, Inc. (symbole boursier : PRVB) a versé un total de 0 dividendes.
Le total des dividendes (ajusté en fonction des divisions d’actions) est de : 0.00
Rendement du dividende (TTM) : 0
Versements de dividendes pour Provention Bio, Inc. (PRVB) de 2026 à 2026
Versements annuels de dividendes
Année Dividende (ajusté pour divisions d’actions) Changez
Pas assez de données pour les dates fournies.
Liste de tous les paiements de dividendes
Année Dividende Changez
Pas assez de données pour les dates fournies.
Dividendes versés par des entreprises similaires ou concurrentes
Entreprise Nombre de paiements de dividendes Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH